Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 145-153, March 2010

Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches

  • Vicki A. Morrison, MD (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 612 467 4135; fax: +1 612 727 5673.

University of Minnesota, Staff Physician, Sections of Hematology/Oncology & Infectious Disease, VAMC, One Veterans Dr, Minneapolis, MN 55417, USA

Infectious complications continue to be a major cause of morbidity and mortality in patients with chronic lymphocytic leukaemia (CLL). The pathogenesis of infections in these patients is multifactorial, related to inherent immune defects and therapy-related immunosuppression. Hypogammaglobulinaemia is an important predisposing factor for infection in all patients. The use of the purine analogues such as fludarabine, and monoclonal antibodies such as rituximab and alemtuzumab, has introduced a new spectrum of infectious complications caused by pathogens such as Pneumocystis, Listeria, mycobacteria, herpesviruses Candida and Aspergillus, related to the cellular immune suppression induced by these agents. This review focusses on the pathogenesis and risk factors for infections in patients with CLL, the spectrum of infectious complications and preventive approaches to infection in these patients, using antimicrobial and immunoglobulin prophylaxis and vaccination strategies.

Keywords: hypogammaglobulinaemia, fludarabine, pentostatin, alemtuzumab, prophylaxis, immunoglobulin

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6926(09)00105-4

doi:10.1016/j.beha.2009.12.004

Best Practice & Research Clinical Haematology
Volume 23, Issue 1 , Pages 145-153, March 2010